A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
Completed · Phase 1
Conditions studied: Overactive Bladder
In brief
The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together
Key facts
- Study ID
- NCT00501267
- Run by
- GlaxoSmithKline
- People needed
- 24
- Starts
- 2007-06-01
- Expected to finish
- 2007-08-01
- Last updated by the study team
- 2015-04-15
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Healthy adult males \& females ages 18-65;
- Body weight >50kg; BMI between 19-32;
- Signed and dated informed consent; QTc Interval <450 msec;
You may not qualify if…
- Resting blood pressure >140/90 mmHg or HR >100 at screening;
- History of drug allergy or other allergy which, in the opinion of the PI, contraindicates their participation;
- Positive urine drug, alcohol or serum pregnancy test at screening and prior to dosing;
- Positive HIV, Hepatitis B, C at screening; use of medications (except acetaminophen)or vitamins or herbal supplements within 7 days or 5 half lives prior to dosing and during study;
- history of urinary retention, gastric retention, and other sever gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma or who are at risk for these conditions;
- history of chronic constipation and/or regular laxative use; donation of more than 500mL of blood within 56 days prior to dosing;
- clinically relevant abnormality identified during screening process or any medical condition or circumstance making the subject unsuitable for participation based on the Investigators assessment
Where it is running
- GSK Investigational Site — Tacoma, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.